Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Results from Phase 2 LILAC study showed litifilimab significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo as measured by the primary...
-
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads to the loss of everyday functions and is uniformly fatalIf approved, tofersen would...
-
Patent covers approved dosing regimen for TECFIDERA and expires in 2028 CAMBRIDGE, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Patent...
-
RESPOND study is actively enrolling, with baseline characteristics reporting infants and toddlers have residual unmet medical needs in multiple areas after gene therapy; SPINRAZA treatment following...
-
The Biogen Foundation has granted $70 million to help underserved communities in advancing science education, health equity, and food securityMore than 61,000 students have benefitted from Biogen’s...
-
AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s DiseaseAlectos to receive a $15 million upfront payment and is...
-
CAMBRIDGE, Mass. and GUANGZHOU, China, June 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today presented positive Phase 3 data for BIIB800...
-
12-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of lifeTofersen also led to robust and sustained...
-
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)MedRhythms to receive a $3 million upfront payment...
-
Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm...